In 35 healthy adults over age 64, 60 daily HBOT sessions at 2.0 ATA increased telomere length by more than 20% across all immune cell types and cut senescent T helper cells by 37%. Those 2020 findings from Shai Efrati’s Sagol Center (Hachmo et al., Aging) remain the single most cited HBOT anti-aging result. The study had no control group and has not been independently replicated as of 2026, so read the numbers alongside that limitation.
Telomere: a protective cap of repeated DNA at the end of a chromosome that shortens each time a cell divides; its length is used as a biomarker of biological age. Senescent cell: a cell that has stopped dividing but resists dying and secretes inflammatory signals (the SASP) that damage neighboring tissue.
What did the Efrati telomere study find?
The study enrolled 35 healthy adults aged 64 and older who each completed 60 daily HBOT sessions at 2.0 ATA with intermittent air breaks. Telomere length and senescent cell populations in peripheral blood mononuclear cells were measured at baseline, after 30 sessions, after 60 sessions, and one to two weeks after treatment ended. Telomeres lengthened by more than 20% in every immune cell type measured, and senescent T helper cells fell by 37%.
| Cell Type | Change at 60 Sessions | p-value |
|---|---|---|
| B cells | +29.39% | p = 0.0001 |
| T helper cells (CD4+) | +23.69% | p = 0.012 |
| T cytotoxic cells (CD8+) | +24.13% | p = 0.0019 |
| Senescent T helper cells | -37.30% | p < 0.0001 |
| Senescent T cytotoxic cells | -10.96% | p = 0.0004 |
The authors put it plainly in the abstract: “Telomeres length of T helper, T cytotoxic, natural killer and B cells increased significantly by over 20% following HBOT” (Hachmo et al., Aging, 2020). It is the largest telomere elongation documented from any single intervention in humans, which is exactly why it demands scrutiny rather than celebration.
How reliable is the HBOT telomere evidence?
Moderately reliable as a signal, weak as proof. The telomere data come from one uncontrolled trial that has not been replicated, so the effect sizes should be read as a hypothesis worth testing, not a settled result. Five limitations shape how much weight the numbers can carry:
- No sham control: this was a prospective trial without randomization or a control group. Participants knew they were receiving HBOT. The telomere and senescence measurements are objective blood assays, which limits placebo influence, but the absence of a comparison arm means normal biological variation cannot be ruled out.
- Small sample and wide variance: n=35, with standard deviations of roughly 23 to 53% on some measures. That spread means some participants likely saw little or no change while others drove the average.
- Single research group: as of 2026 no independent team has replicated the specific telomere lengthening. A 2022 report by Maroon described telomere doubling in a single subject (the author himself), which is a case report, not replication.
- Immune cells only: the lengthening was measured in peripheral blood immune cells. Whether other tissues respond the same way is unknown.
- Durability unknown: follow-up ended a few weeks post-treatment. Whether the gains persist has not been studied.
Before this study, interventions like exercise, meditation, and diet had shown modest slowing of telomere shortening but nothing approaching active lengthening of this magnitude. That novelty is precisely what makes independent replication the deciding test.
Is there controlled evidence that HBOT helps aging?
Yes, for physical capacity. A 2024 randomized controlled trial by Hadanny and colleagues in BMC Geriatrics gives the strongest evidence in this area because it had a control group. It enrolled 63 adults over 64 (30 HBOT, 33 control) and ran the same 60-session, 2.0 ATA, 90-minute protocol over 12 weeks.
- VO2Max/kg: +1.91 ml/kg/min, effect size 0.455 (p=0.003)
- VO2 at first ventilatory threshold: +160 ml/min, effect size 0.617 (p<0.001)
- Cardiac blood flow: effect size 0.797 (p=0.008)
- Cardiac blood volume: effect size 0.896 (p=0.009)
These are moderate to large effect sizes on hard physiological endpoints, from a randomized design. They do not confirm the telomere claim (different outcome, different mechanism), but they establish that a 60-session HBOT course can measurably improve physical capacity in older adults.
How could HBOT lengthen telomeres?
The leading explanation is the hyperoxic-hypoxic paradox. Kamat, Mendelsohn, and Larrick described it in a 2021 review in Rejuvenation Research: during a session tissues are flooded with oxygen, and when the session ends and pressure returns to normal, tissues sense a relative oxygen drop that mimics hypoxia at the cellular level. This cycling activates HIF-1alpha (normally a low-oxygen signal) and induces SIRT1, a longevity-associated regulator. Their key point is that SIRT1 is induced by hyperoxia but suppressed by chronic hypoxia, so intermittent HBOT engages both pathways in a way neither steady state does. This is a plausible mechanism, not proof of the clinical claim.
What does the skin aging evidence show?
A companion 2021 study from the same group examined skin biopsies from 13 participants before and after HBOT (Hachmo et al., Aging). It reported significant increases in collagen density (p<0.001, effect size 1.10), elastic fiber length (p<0.0001, effect size 2.71), and blood vessel formation (p=0.02, effect size 1.00), plus decreases in fiber fragmentation and tissue senescent cells. It was the first human study to show HBOT modulating skin aging at the tissue level, but the sample was only 13 people with no control group, which is why the evidence meter grades it emerging. Our page on hyperbaric chamber skin rejuvenation covers the cosmetic angle in more detail.
What does the HBOT anti-aging protocol look like?
Every study above used effectively the same protocol, so the “dose” is well defined even if the outcomes are not settled:
- Pressure: 2.0 ATA (hard chamber only; soft home units at 1.3 ATA do not reproduce this)
- Oxygen: 100% medical-grade oxygen via mask
- Session structure: 90 minutes total, three 20-minute oxygen periods with 5-minute air breaks
- Frequency: 5 sessions per week
- Duration: 60 sessions over 12 weeks
- Cost: roughly $12,000 to $24,000 at clinical facilities
How does HBOT compare with other longevity interventions?
| Intervention | Telomere Effect | Senolytic Effect | Evidence Level |
|---|---|---|---|
| HBOT (Hachmo 2020 protocol) | >20% lengthening (no control) | -11 to -37% (no control) | 1 uncontrolled prospective study (n=35), not replicated |
| Exercise | Slows shortening | Modest | Multiple large observational studies |
| Dasatinib + Quercetin | None demonstrated | Significant clearance | Phase II human trials |
| NAD+ supplementation | None demonstrated | Indirect | Animal and early human data |
The honest summary: HBOT shows the most eye-catching telomere number of any human intervention, from the weakest study design of the four. For a broader view of the aging evidence, see our guide to hyperbaric chamber anti-aging protocols and HBOT for longevity and performance. For how these trials sit within the wider literature, see our HBOT research overview.
Sources
- Hachmo Y, Hadanny A, Abu Hamed R, et al. “Hyperbaric oxygen therapy increases telomere length and decreases immunosenescence in isolated blood cells: a prospective trial.” Aging, 2020;12(22):22445-22456. doi:10.18632/aging.202188 (PMID 33206062)
- Hachmo Y, Hadanny A, Mendelovic S, et al. “The effect of hyperbaric oxygen therapy on the pathophysiology of skin aging: a prospective clinical trial.” Aging, 2021;13(22):24500-24510. doi:10.18632/aging.203701 (PMID 34784294)
- Hadanny A, Sasson E, Copel L, et al. “Physical enhancement of older adults using hyperbaric oxygen: a randomized controlled trial.” BMC Geriatrics, 2024;24:537. doi:10.1186/s12877-024-05146-3 (PMID 38961397)
- Kamat S, Mendelsohn A, Larrick J. “Rejuvenation Through Oxygen, More or Less.” Rejuvenation Research, 2021;24(2):158-163. doi:10.1089/rej.2021.0014 (PMID 33784834)
- Fu Q, Duan R, Sun Y, Li Q. “Hyperbaric oxygen therapy for healthy aging: From mechanisms to therapeutics.” Redox Biology, 2022;53:102352. doi:10.1016/j.redox.2022.102352 (PMID 35649312)
- Maroon JC. “The effect of hyperbaric oxygen therapy on cognition, performance, proteomics, and telomere length.” Frontiers in Neurology, 2022;13:949536. doi:10.3389/fneur.2022.949536 (PMID 35968296)
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
